SCHEMBL18640948

SCHEMBL18640948

CC(C)(C)OC(=O)N1C(=O)NCC1c1cc(F)cc(F)c1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 3/20 0.40
KDM4E B2RXH2 1/20 0.36
MAPT P10636 1/20 0.36
THRB P10828 1/20 0.36
DPP4 P27487 1/20 0.34
HDAC1 Q13547 2/20 0.33
P2RX7 Q99572 1/20 0.33
DDB1 Q16531 1/20 0.33
CRBN Q96SW2 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
HDAC5 Q9UQL6 1/20 0.33
TACR1 P25103 1/20 0.32
HDAC2 Q92769 1/20 0.32
NR1H2 P55055 1/20 0.32
NR1H3 Q13133 1/20 0.32
MAPK1 P28482 1/20 0.32
GPR119 Q8TDV5 1/20 0.32
HRH3 Q9Y5N1 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18640934 0.87 RORC (0.39) RIPK1HDAC1TACR1HDAC2
SCHEMBL18640901 0.84 DPP4 (0.37) RIPK1KDM4EMAPTTHRBDPP4
SCHEMBL18448056 0.81 RIPK1 (0.49) RIPK1NR1H2NR1H3MAPK1GPR119
SCHEMBL18640858 0.80 TP53 (0.40) KDM4EGPR119
SCHEMBL18640891 0.80 NTRK1 (0.41) GPR119
SCHEMBL18640857 0.80 RIPK1 (0.42) RIPK1KDM4EMAPTTHRBMAPK1
SCHEMBL25007084 0.79 RIPK1 (0.36) RIPK1KDM4EMAPTTHRBDDB1
SCHEMBL979259 0.78 RIPK1 (0.40) RIPK1KDM4EMAPTTHRBDPP4
SCHEMBL1273810 0.77 RIPK1 (0.39) RIPK1KDM4EMAPTTHRBDPP4
SCHEMBL1274378 0.76 RIPK1 (0.38) RIPK1KDM4EMAPTTHRBDPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180237441-A1 Chemical Compounds GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2018-08-23 US disclosed
EP-3350185-A1 1-PHENYLPYRROLIDIN-2-ONE DERIVATIVES AS PERK INHIBITORS Glaxosmithkline Intellectual Property (No. 2) Limited (GB) 2018-07-25 EP disclosed
WO-2017046737-A1 1-PHENYLPYRROLIDIN-2-ONE DERIVATIVES AS PERK INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2017-03-23 WO disclosed
WO-2017046737-A1 1-PHENYLPYRROLIDIN-2-ONE DERIVATIVES AS PERK INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2017-03-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180237441-A1 Chemical Compounds PSEN1, IRS1, CPT1A RIPK1 154/4885KDM4E 4453/4885MAPT 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.